Edwards Lifesciences wins appeal in Medtronic patent fight
WASHINGTON Nov 13 (Reuters) - Edwards Lifesciences LLC Corp won a round in a patent fight with Medtronic Inc's CoreValve unit on Tuesday as a federal appeals court upheld a $74 million lower court judgment involving infringement of patented heart valve technology.
The U.S. Court of Appeals for the Federal Circuit said on Tuesday it was upholding a decision by a federal court in Delaware that Medtronic's device infringed a patent owned by Edwards. The court awarded $74 million in lost profits and royalties.
The device in question is an artificial heart valve that can be implanted without resorting to open heart surgery.
But the district court declined to issue an order banning sales of Medtronic's infringing product, and the appeals court send the case to the lower court to reconsider the denial of the injunction.
In early October, Edwards cut its revenue forecast for the third quarter, as sales of its unique heart valve that was expected to drive results fell short of estimates.
Edwards estimated total revenue of about $448 million for the quarter that ended Sept. 30, down from its previous outlook of between $465 million to $485 million.
The case is at the U.S. Court of Appeals for the Federal Circuit. It is Edwards Lifesciences AG v. Medtronic Corevalve, LLC, No. 2011-1215,-1257.
- Exclusive: Secret contract tied NSA and security industry pioneer |
- Seattle students protest gay Catholic school teacher's resignation
- Accused Colorado theater gunman competent to stand trial, evaluators say
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
- Harsh weather, floods challenge U.S. holiday travelers